|
|
|
|
|
|
| |
| FDA Cancels Cymbalta Panel Meeting |
| 01/06/2010 |
| |
|
Federal Register Notice: FDA’s Anesthetic and Life Support Drugs Advisory Committee scheduled 1/28 to discuss the available safety and efficacy data for Eli Lilly’s NDA for Cymbalta capsules as they relate to the proposed indication of treatment of chronic pain is canceled. This will allow time for the agency to review new information relevant to the benefit risk balance for the proposed new indication. The agency intends to continue evaluating the application and, as needed, will announce future meeting dates in the Federal Register. To view this notice, click here. |
| |
|
| |
| |
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.
|
|
RSS
